Summit Therapeutics Inc’s filing revealed that its Chief Executive Officer Zanganeh Mahkam acquired Company’s shares for reported $0.2 million on Mar 27 ’24. In the deal valued at $3.72 per share,54,321 shares were bought. As a result of this transaction, Zanganeh Mahkam now holds 24,923,800 shares worth roughly $442.9 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Zanganeh Mahkam bought 30,000 shares, generating $112,500 in total proceeds. Upon buying the shares at $3.75, the Chief Executive Officer now owns 30,000 shares.
Before that, Zanganeh Mahkam bought 26,000 shares. Summit Therapeutics Inc shares valued at $96,720 were divested by the Chief Executive Officer at a price of $3.72 per share. As a result of the transaction, Zanganeh Mahkam now holds 520,814 shares, worth roughly $9.25 million.
JMP Securities initiated its Summit Therapeutics Inc [SMMT] rating to a Mkt outperform in a research note published on November 04, 2024; the price target was $32. A number of analysts have revised their coverage, including Citigroup’s analysts, who decreased its forecast for the stock in late September from “a Buy” to “a Neutral”. H.C. Wainwright began covering SMMT with “Buy” recommendation on August 12, 2024. Citigroup started covering the stock on May 07, 2024. It rated SMMT as “a Buy”.
Price Performance Review of SMMT
On Tuesday, Summit Therapeutics Inc [NASDAQ:SMMT] saw its stock fall -3.89% to $17.77. Over the last five days, the stock has lost -7.40%. Summit Therapeutics Inc shares have risen nearly 580.84% since the year began. Nevertheless, the stocks have risen 734.27% over the past one year. While a 52-week high of $33.89 was reached on 09/16/24, a 52-week low of $2.05 was recorded on 05/28/24. SMA at 50 days reached $20.13, while 200 days put it at $11.24.
Levels Of Support And Resistance For SMMT Stock
The 24-hour chart illustrates a support level at 16.69, which if violated will result in even more drops to 15.62. On the upside, there is a resistance level at 18.67. A further resistance level may holdings at 19.58. The Relative Strength Index (RSI) on the 14-day chart is 39.99, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.64, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 76.05%. Stochastics %K at 14.80% indicates the stock is a buying.
How much short interest is there in Summit Therapeutics Inc?
A steep rise in short interest was recorded in Summit Therapeutics Inc stocks on 2024-11-15, growing by 0.54 million shares to a total of 15.99 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-15 was 15.45 million shares. There was a rise of 3.38%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 26, 2024 when Stifel began covering the stock and recommended ‘”a Buy”‘ rating along with a $8 price target.
